Lifecore Biomedical

LFCR

Market cap $288M

Overview Fund Activity

7.70 USD

-0.16

2.04%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

7.86

+0.16

2.08%

1 day

-2.04%

5 days

9.07%

1 month

4.05%

3 months

13.07%

6 months

17.56%

Year to date

15.62%

1 year

51.57%

5 years

-20.45%

10 years

-41.31%

About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

Employees: 406

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 18

16% more capital invested

Capital invested by funds: $190M [Q1] → $221M (+$30.6M) [Q2]

0.38% more ownership

Funds ownership: 66.19% [Q1] → 66.57% (+0.38%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 86 [Q1] → 85 (-1) [Q2]

36% less call options, than puts

Call options by funds: $76K | Put options by funds: $118K

See Fund Rankings

Financial journalist opinion

Based on 4 articles about LFCR published over the past 30 days

Zacks Investment Research

Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?

Lifecore Biomedical, Inc. (LFCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Paul Josephs - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Good afternoon. Thanks for joining us.

Lifecore Biomedical, Inc. (LFCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brunswick, NJ.

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

Lifecore Biomedical to Participate in Upcoming Investor Conferences

CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore's participation are as follows:

Lifecore Biomedical to Participate in Upcoming Investor Conferences

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

The Motley Fool

Lifecore (LFCR) Q4 Revenue Beats 3%

Lifecore Biomedical (LFCR 0.78%), a contract development and manufacturing company focused on sterile injectable pharmaceuticals and hyaluronic acid (HA) products, reported fiscal fourth-quarter 2025 results on August 7, 2025. The company reported GAAP revenue of $36.4 million in Q4 FY2025, exceeding the analyst estimate of $35.4 million (GAAP), and narrowed its GAAP loss per share to $(0.06), beating the forecast $(0.10) GAAP loss.

Lifecore (LFCR) Q4 Revenue Beats 3%

Zacks Investment Research

Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.

Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance ; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the fourth quarter and fiscal year 2025.

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Laughing Water Capital's Top 5 Positions For Q2 2025

Lifecore Biomedical is positioned for margin expansion and likely acquisition, supported by industry trends and potential M&A multiples above current share price. NextNav is favorably placed for FCC spectrum approval, with strong national security tailwinds and potential for significant share price appreciation upon monetization. SECURE Waste Infrastructure offers downside protection, recurring cash flows, aggressive buybacks, and potential for 30-40% equity CAGR if valuation re-rates.

Laughing Water Capital's Top 5 Positions For Q2 2025

See News Rankings

Charts implemented using Lightweight Charts™